Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
AveXis, Inc. (AVXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/11/2018 SC 13G/A FMR LLC reports a 0% stake in AVEXIS INC
06/06/2018 CT ORDER Form CT ORDER - Confidential treatment order:
06/04/2018 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
05/23/2018 EFFECT Form EFFECT - Notice of Effectiveness:
05/17/2018 SC 13D/A ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 0% stake in AveXis, Inc.
05/16/2018 CT ORDER Form CT ORDER - Confidential treatment order:
05/15/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
05/15/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/15/2018 8-K Resignation/termination of a director
Docs: "AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"AMENDED AND RESTATED BY-LAWS"
05/15/2018 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
05/15/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
05/15/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
05/10/2018 SC 13G/A FMR LLC reports a 5.9% stake in AVEXIS INC
05/04/2018 10-Q Quarterly Report for the period ended March 31, 2018
05/03/2018 8-K Quarterly results
Docs: "AveXis Reports First Quarter 2018 Financial and Operating Results"
05/03/2018 GN AveXis Reports First Quarter 2018 Financial and Operating Results
05/01/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
05/01/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
05/01/2018 GN AveXis Provides Update on Proposed Acquisition by Novartis AG
04/30/2018 10-K/A Annual Report for the period ended December 31, 2017 [amend]
04/25/2018 8-K Quarterly results
04/24/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology"
04/20/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
04/20/2018 SC 13D ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 6% stake in AveXis, Inc.
04/17/2018 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
04/17/2018 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
04/10/2018 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
04/09/2018 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
04/09/2018 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
04/09/2018 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
04/09/2018 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, among Novartis AG, Novartis AM Merger Corporation, and AveXis, Inc",
"Amendment to the Amended and Restated Bylaws of AveXis, Inc",
"Press Release of AveXis, Inc."
04/08/2018 GN AveXis Enters Agreement to be Acquired by Novartis AG for $8.7 billion
03/27/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1 Chicago, Ill. — AveXis, Inc. , a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that Japan's Ministry of Health, Labour and Welfare awarded the company's initial product candidate, AVXS-101, SAKIGAKE Designation for the treatment of spinal muscular atrophy Type 1. The designation was based on data from the Phase 1 clinical trial of the company's proprietary gene therapy. SAKIGAKE is intended to promote research and development in Japan for innovative new medical products that satisfy certain criteria, such as the severity of the intended indication, by providing prioritized consultation review dur..."
03/27/2018 GN AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy